Biomimetic elasticity compressed assembly controls rapid intracerebral drug release to reverse microglial dysfunction.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40305624.
- Also identified by DOI 10.1126/sciadv.adr0656 and PMC identifier 12042905.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The regulation of microglial dysfunction has become increasingly prominent in treatment of Alzheimer's disease (AD). Herein, we develop a scalable polymer-involved biomimetic assembly that responds to intracerebral reactive oxygen species (ROS) for elastic spreading and concentration-dependent drug therapy. Structurally, a polymer of thermally sensitive deformation is selected for hydrophobic loading of curcumin (Cur) and coordinative grafting onto ultrasmall ceria (CeO<sub>2</sub>) by elastic compression at transition temperature, which is further sealed by self-polymerized dopamine with apolipoprotein decoration to improve intracerebral shuttling. When triggered by ROS in the lesions, burst exposure of Cur and polymer-linked CeO<sub>2</sub> (PCeO<sub>2</sub>) is achieved. The concentrated Cur switches amyloid-β (Aβ)-activated microglia into normal for mobilizing phagocytosis, and CeO<sub>2</sub> has sustainable antioxidant capacity to prevent microglial mitochondrial damage after phagocytosis of PCeO<sub>2</sub>-captured Aβ. After administration, our findings reveal microglia-mediated Aβ clearance, neuroprotection, and ROS elimination in AD mice. Collectively, this biomimetic assembly provides a promising approach in AD treatments.
Medical subject headings
- Microglia
- Curcumin
- Alzheimer Disease
- Biomimetics
- Drug Liberation
- Biomimetic Materials